Observational study investigating Ectoin® Rhinitis Nasal Spray as natural treatment option of acute rhinosinusitis compared to treatment with Xylometazoline

Abstract

Introduction Symptomatic relief of acute rhinosinusitis is commonly achieved with nasal decongestants. The current observational study investigated the efficacy and safety of treatment of acute rhinosinusitis with Ectoin® Rhinitis Spray compared to or in combination with Xylometazoline-containing decongesting nasal spray. Methods Patients with acute rhinosinusitis applied either Ectoin® Rhinitis Spray, Xylometazoline nasal spray or a combination of both products. Rhinosinusitis symptoms were assessed, and nasal oedema and endonasal redness were determined by rhinoscopy. Patient diaries based on the validated SNOT (Sino Nasal Outcome Test) questionnaire evaluated rhinosinusitis parameters over time and influences of the disease on quality of life. Following treatment, investigators and patients judged the efficacy and tolerability. Results Ectoin® Rhinitis Spray diminished common rhinosinusitis symptoms such as nasal obstruction, nasal secretion, facial pain/headache, and smell/taste impairment. Upon treatment over 7 days, rhinosinusitis sum scores decreased statistically significantly (p < 0.001) by − 64.25%, which was comparable to that achieved with Xylometazoline-containing decongesting nasal spray (− 67.60%). No side effects were observed during treatment with Ectoin® Rhinitis Spray, whereas treatment with Xylometazoline-containing nasal spray resulted in nasal mucosa dryness. Concomitant treatment with both products diminished the development of nasal dryness and required fewer applications of Xylometazoline-containing nasal spray. Conclusion Ectoin® Rhinitis Spray is an effective, natural treatment option for acute rhinosinusitis, which may be used as monotherapy or as add-on treatment with a Xylometazoline-containing nasal spray. The concomitant use of Ectoin® Rhinitis Spray might reduce the needed dose of decongestant nasal spray and counteract bothersome side effects such as dry nasal mucosa. Trial registration The current study was registered in the ClinicalTrials.gov database under the identifier: NCT03693976 (date of registration: Oct 3, 2018).

Protective effects of ectoine on articular chondrocytes and cartilage in rats for treating osteoarthritis

“…In addition, ectoine protects the ileal mucosa from ischemia-reperfusion injury, a common complication after small bowel transplantation [ 32 ]. Several recent studies reported that ectoine-containing sprays effectively treat acute pharyngitis, allergic rhinitis, and rhinoconjunctivitis [ 33 , 34 ]. However, the effects of ectoine on OA treatment have not been reported to date.…”

“…Several recent studies reported that ectoine-containing sprays effectively treat acute pharyngitis, allergic rhinitis, and rhinoconjunctivitis [33,34]. However, the effects of ectoine on OA treatment have not been reported to date.…”

Contemporary Use Of Topical Decongestants: An Indian Perspective

“…The majority of doctors in this study reported that the use of xylometazoline with sorbitol and hypromellose also eases nasal dryness. This property of the formulation is beneficial because dryness of the nasal mucosa can lead to pain and nosebleeds, increasing the burden on patients [8]. Therefore, it can be concluded that xylometazoline with sorbitol and hypromellose is an effective treatment for nasal congestion that also relieves nasal dryness.…”

“…Xylometazoline hydrochloride is a well-established topical nasal decongestant. This sympathomimetic drug acts selectively on α-adrenergic receptors (alpha-adrenergic agonist) [8]. Patients report relief from nasal congestion within 2 minutes of use of xylometazoline, and the increase in nasal conductance is five times higher than that noted with oral decongestants [9].…”